WIPF3: A Protein Regulating WAS/WASL Signaling in Neurons and Other Cell Types

WIPF3: A Protein Regulating WAS/WASL Signaling in Neurons and Other Cell Types

WIPF3 (WAS/WASL interacting protein family member 3) is a protein that is expressed in various cell types of the human body, including neurons, muscle cells, and immune cells. It is a member of the WIPF3 family, which is known for its role in regulating protein-protein interactions, specifically in the WAS/WASL signaling pathway.

WAS/WASL is a well-known signaling pathway that plays a crucial role in the regulation of cell proliferation, differentiation, and survival. It is a transcription factor that can activate or repress gene expression, and it is involved in the development and maintenance of various tissues and organs in the body. WAS/WASL signaling is also associated with the regulation of inflammation, DNA damage repair, and cell survival.

WIPF3 is a key protein that interacts with WAS/WASL in the regulation of cellular processes. It is a protein that can form a complex with WAS/WASL, which allows it to interact with the transcription factor and influence its activity. This interaction between WIPF3 and WAS/WASL is critical for the regulation of various cellular processes, including cell proliferation, differentiation, and survival.

WIPF3 functions as a negative regulator of the WAS/WASL signaling pathway. It can inhibit the activity of WAS/WASL by binding to its regulatory domain, which is located in the N-terminus of the protein. This interaction between WIPF3 and WAS/WASL allows the transcription factor to regulate the activity of various gene products, including proteins involved in cell signaling and inflammation.

WIPF3 is also involved in the regulation of cellular processes that are independent of the WAS/WASL signaling pathway. For example, it is involved in the regulation of cell adhesion, migration, and the production of cell surface antigens. It is also involved in the regulation of cytoskeletal structure and the distribution of organelles in the cell.

As a drug target or biomarker, WIPF3 is a promising target for the development of new therapies for various diseases. Its involvement in the regulation of cellular processes makes it an attractive target for the treatment of diseases that are characterized by the disruption of normal cellular processes, such as cancer, neurodegenerative diseases, and autoimmune diseases.

WIPF3 is also a potential biomarker for various diseases. Its involvement in the regulation of cellular processes makes it an attractive target for the detection of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The disruption of WIPF3 function has been observed in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Conclusion

In conclusion, WIPF3 is a protein that is involved in the regulation of various cellular processes, including cell proliferation, differentiation, and survival. It is a member of the WIPF3 family and can form a complex with WAS/WASL, which allows it to interact with the transcription factor and influence its activity. The disruption of WIPF3 function has been observed in various diseases, making it a potential drug target or biomarker. Further research is needed to fully understand the role of WIPF3 in the regulation of cellular processes and its potential as a drug target or biomarker.

Protein Name: WAS/WASL Interacting Protein Family Member 3

Functions: May be a regulator of cytoskeletal organization. May have a role in spermatogenesis (By similarity)

The "WIPF3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WIPF3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3 | WWOX | WWP1 | WWP2 | WWTR1 | WWTR1-AS1 | XAB2 | XACT | XAF1 | XAGE-4 | XAGE1A | XAGE1B | XAGE1D | XAGE2 | XAGE3 | XAGE5 | XBP1 | XCL1 | XCL2 | XCR1 | XDH | XG | XGY2 | XIAP | XIRP1 | XIRP2 | XIST | XK | XKR3 | XKR4 | XKR5 | XKR6 | XKR7 | XKR8 | XKR9 | XKRX | XKRY | XKRYP7 | XLOC_007697 | XLOC_008559 | XLOC_009911 | XNDC1N | XPA | XPC | XPC complex | XPNPEP1 | XPNPEP2 | XPNPEP3 | XPO1 | XPO4 | XPO5 | XPO6 | XPO7 | XPOT | XPR1